Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Acute Coronary Syndrome and Its Correlation

Deepak Bhat Seetharama1, Kavya Prasad1, Varsha Rakshitha Prakash2

  • 1Internal Medicine, M.S. Ramaiah Medical College, Bengaluru, IND.

Cureus
|April 21, 2026
PubMed

Insights

Higher platelet-to-lymphocyte ratio (PLR) indicates increased coronary artery disease severity and a greater risk of major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients. This simple inflammatory marker aids in risk assessment.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Biomarkers

Background:

  • Acute coronary syndrome (ACS) presents significant morbidity and mortality, driven by inflammatory and thrombotic processes.
  • The platelet-to-lymphocyte ratio (PLR) is an emerging inflammatory marker with potential prognostic value in cardiovascular diseases.

Purpose of the Study:

  • To investigate the association between the platelet-to-lymphocyte ratio (PLR) and major adverse cardiovascular events (MACE) in patients diagnosed with acute coronary syndrome (ACS).

Main Methods:

  • A prospective observational study involving 640 consecutive adult ACS patients.
  • Platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and SYNTAX scores were calculated from blood samples collected within 12 hours of symptom onset.
  • In-hospital MACE (heart failure, recurrent myocardial infarction, death) were recorded, with multivariate regression analysis performed for confounding variables.

Main Results:

  • Patients experiencing MACE exhibited significantly higher PLR and NLR values and lower ejection fraction (EF) compared to those without MACE (p < 0.001).
  • A higher PLR correlated positively with NLR and SYNTAX I score, and negatively with EF.
  • Elevated PLR was consistently observed across ACS subgroups (NSTEMI, STEMI, unstable angina) and associated with increased MACE incidence (49.38% overall).

Conclusions:

  • Higher platelet-to-lymphocyte ratio (PLR) levels in acute coronary syndrome (ACS) patients are linked to more severe coronary artery disease and a higher risk of in-hospital major adverse cardiovascular events (MACE).
  • PLR may serve as a valuable, accessible biomarker for augmenting risk stratification in ACS patients.
  • Further multicenter studies are warranted to confirm the prognostic utility of PLR in ACS.